title: Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted.
authors.affiliation: Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
authors.forename: Joshua M
authors.initials: JM
authors.lastname: Sharfstein
authors.affiliation: Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle3Group Health Research Institute, Group Health Cooperative, Seattle, Washington.
authors.forename: Bruce M
authors.initials: BM
authors.lastname: Psaty
mesh_terms: D019440:Anti-Obesity Agents / Q000009:adverse effects*; D016642:Bupropion / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D057239:Early Termination of Clinical Trials; D005260:Female; D006801:Humans; D008297:Male; D009271:Naltrexone / Q000009:adverse effects*; D009765:Obesity / Q000188:drug therapy*
chemical_list: D019440:Anti-Obesity Agents; D016642:Bupropion; D009271:Naltrexone